Includes a one-time $1.35 billion Acquired In-Process R&D charge related to the in-licensing agreement with 3SBio, Inc. recorded in the third quarter of 2025 with an unfavorable impact of ...

Includes a one-time $1.35 billion Acquired In-Process R&D charge related to the licensing agreement with 3SBio, Inc. that will be recorded in the third quarter of 2025 with an expected unfavorable ...

Pfizer Inc. (NYSE:PFE) is one of the most buzzing stocks to invest in according to hedge funds. Earlier on December 17, ...

$2.2 billion invested in internal research and development projects, and Approximately $90 million invested in business development transactions. Returning capital directly to shareholders through ...

Second-quarter 2025 Cost of Sales(3) as a percentage of revenues increased by 0.9 percentage points compared to the prior-year quarter, driven primarily by the non-recurrence of a favorable revision ...

Global pharmaceutical company Pfizer (NYSE:PFE) announced in Q2 CY2025, with sales up 10.3% year on year to $14.65 billion. The company expects the full year’s revenue to be around $62.5 billion, ...

Pfizer (PFE) reported mixed first quarter earnings Tuesday, as the company focuses on gaining investor interest in its near-term pipeline amid a volatile macro environment in the markets. Pfizer ...

Third-quarter 2025 Cost of Sales(3) as a percentage of revenues decreased by 4.7 percentage points compared to the prior-year quarter, primarily driven by (i) a favorable revision of our estimate of ...

Pfizer Inc. (NYSE:PFE) on Friday released data from Phase 3 BREAKWATER trial evaluating BRAFTOVI (encorafenib) in combination with cetuximab (marketed as ERBITUX) and mFOLFOX6 (fluorouracil, ...